Breast Cancer Treatment in Those Over 70 Can Be Reduced

Oncologists faced with treating older women with breast cancer often must decide if the treatment may be more detrimental than the cancer. A study published in JAMA Network Open by researchers at UPMC Hillman Cancer Center and the University of Pittsburgh School of Medicine sheds new light on this choice and suggests the rate of cancer recurrence or survival may be no different in treated vs. untreated elderly patients diagnosed in the early stages of the cancer diagnosed most commonly in women. McGowan Institute for Regenerative Medicine affiliated faculty member Steffi Oesterreich, PhD, the Shear Family Foundation Chair in Breast Cancer Research Professor and Vice-Chair Department of Pharmacology and Chemical Biology, University of Pittsburgh; Co-Leader Cancer Biology Program, UPMC Hillman Cancer Center (UPMC HCC); and Co-Director Women’s Cancer Research Center, UPMC HCC and Magee Womens Research Institute, is a co-author on the study.

“As a breast surgeon, I want to give my patients the best chance of survival with the best quality of life,” said senior author Priscilla McAuliffe, MD, PhD, surgical oncologist at UPMC HCC and attending surgeon in the Department of Surgery at Pitt. “However, we have found that overtreatment of early-stage breast cancer in older patients may actually cause harm while not improving recurrence or survival rates.”

Despite guidelines recommending the de-escalation of treatment among older women with early-stage cancer, there has been no definitive study of this patient cohort, who often are excluded in clinical trials because of their age.

To determine whether patients were being overtreated, the researchers analyzed deidentified data from more than 3,000 women over the age of 70 who were diagnosed with ER-positive, HER2-negative breast cancer from 2010 to 2018. Age 70 was used because clinical trials in breast cancer don’t often include women in this age category. The data, collected at 15 UPMC Hillman Cancer Center community and academic sites, were evaluated with the UPMC Network Cancer Registry, which tracks cancer patients using UPMC’s electronic health record system.

The study looked at two procedures: sentinel lymph node biopsy (SLNB), which is a surgical procedure to remove the lymph nodes from the underarm to determine if the cancer has spread beyond the breast, and radiotherapy (RT), which is standard treatment after breast-conserving surgery, given in multiple doses to control or kill any residual tumor. Side effects including nerve pain, lymphedema and skin irritation can sometimes occur after these procedures, which may be more difficult for the older patient to overcome.

The researchers found that the number of SLNB and RT procedures among patients over age 70 remained high at 65.3% and 54.4% respectively. The rates of SLNB also steadily increased by 1% per year, while rates of RT declined by 3.4% per year over the study period.

Most importantly, they found that the rates of disease recurrence or survival remained the same, whether the carefully selected patients received SLNB or RT, or not—no matter their comorbidities or tumor grade.

“This study is an example of how we can use big data to deliver on the promise of precision medicine—getting the right treatment to the right patient at the right time,” said Adrian Lee, PhD, investigator at the Women’s Cancer Research Center at UPMC HCC and Magee Womens Research Institute, and director of the UPMC/Pitt Institute of Precision Medicine. “Sometimes—as it happens to be in this case—that could mean deciding not to provide a certain treatment to ensure better care for the patient.”

The American Society of Breast Surgeons has released its second list of specific tests or procedures that clinicians and patients should question as part of Choosing Wisely®, an initiative of the ABIM Foundation. Dr. Lee hopes this study will further validate that a de-escalation of treatment for certain breast cancers will not affect the quality of life or outcome for patients and that SLNB and RT can safely be omitted.

“Our study is unique in that we were able to look at very granular patient data, thanks to the size of our health system and the availability of electronic medical records, which makes the findings more robust than any other such study to date,” said Neil Carleton, lead author and an MD/PhD student at Pitt. “This is the result of an incredible collaborative of researchers, oncologists and clinical analytics experts.”